AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|
25.1 C
New York
Thursday, September 3, 2026

Tag: drug

newssourceFORcompanyinformationcontent1releasesmarket

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar’s Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Cosmos Health signs distribution agreement with IMC, owner of Qatar's largest pharmacy chain. Secures purchase order of 31,000 Sky Premium Life units.

FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health

If finalized, rule would level the playing field between American and foreign businesses 
If finalized, rule would level the playing field between American and foreign businesses

Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets

MUMBAI, India and NAPLES, Fla., June 26, 2026 /CNW/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN)...

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy

The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously presented at the 2025 American Society...

Complex Small Molecules Are Changing Drug R&D

WuXi AppTec details how structural complexity in protein degraders, covalent agents, and kinase programs is reshaping what integrated CRDMOs must deliver.

Merz Aesthetics Launches Ultherapy Mask – PDRN Peptide Radiance in Malaysia and Appoints Scha Alyahya as the First Ultherapy PRIME Brand Ambassador

Ultherapy Mask - PDRN Peptide Radiance now available in Malaysia exclusively through PRIME certified clinicsThe at-home mask is designed to support hydration, skin recovery,...

Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility

Allschwil, Switzerland – June 26, 2026
Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously announced senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP.

Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes

NEW YORK, June 25, 2026 Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges...

Everest Medicines Announces China NMPA Acceptance of the Biologics License Application for LEROCHOL® in Adults with Hypercholesterolemia

SHANGHAI, June 26, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

Quantum AI Microcities Project Launch First Global AGI Communities Clinical Trial Network (Veterans First for America)

Eikon Therapeutics to Join the Russell 3000® Index

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community 
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

JellyFil Discloses 2026 Botanical Ingredient Sourcing, cGMP Manufacturing Standards, Caffeine Content, and Consumer Safety Considerations for Its Premium Gummy Dietary Supplement

JellyFil discloses 2026 gummy supplement ingredient origins, cGMP manufacturing standards, caffeine content, and drug interaction guidance.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers